Neurobehavioral Changes Following Spaceflight Stressors
University of Pennsylvania · with Uniformed Services University of the Health Sciences, University of Florida · NCT07293494
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 21–60 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 56
- US sites recruiting
- 1
- Study start
- August 4, 2026
- Record last updated
- August 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study aims to investigate the impairing effects of known central nervous system (CNS) stressors in a controlled environment in order to predict and mitigate analogous risks in spaceflight. Up to 56 healthy individuals aged 25-60 will spend approx. 110 hours in a laboratory, where they will be exposed to 27 hours of sleep deprivation and will consume alcohol to reach a BAC of 0.08 on a separate day. They will perform cognitive and sensorimotor tasks and undergo MRIs and blood draws.
Being studied: Alcohol Administration; Sleep Deprivation; Control
Conditions: Stressor, Individual; Alcohol Impairment; Sleep Deprivation; Impairment, Cognitive
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age between 21-60 years.
- Free of psychological, psychiatric or physical conditions that preclude participation.
- BMI between 18.5 and 35.
- Self-reported regular sleep schedule; able to maintain their sleep schedule during the course of the study.
- Self-reported sleep duration of 6-8.5 h per night (verified by daily logs).
- Ability to read/write English.
- Able to stand unassisted for up to 10 minutes at a time and able to lift arms above head.
Exclusion Criteria
- Alcohol or drug abuse in the past year based upon history and urine toxicology screen.
- Potential alcohol abuse or heavy drinking in the past year, based on self-report (AUDIT-C Q2 score above 1 or Q3 score above 2).
- Alcohol-naive based on self-report (AUDIT-C Q1 score of 0).
- Allergies, conditions or circumstances that preclude alcohol consumption, including use of medication or supplements (prescription or over the counter) that could interfere with study participation or make it hazardous for a subject to partake (e.g., anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified), or for which alcohol consumption should be limited or avoided (e.g. items identified on NIAAA's 'Harmful Interactions' list).
- Cultural or personal beliefs that preclude alcohol consumption.
- Body Mass Index ≤18.5 or ≥ 35.
- Current smoker/tobacco user or using nicotine replacement therapy. Those that have been nicotine-free for ≥ 30 days may be included.
- Excessive caffeine consumption (> 650mg/day combining all caffeinated drinks regularly consumed during the day).
- Acute, chronic, or debilitating medical conditions, major Axis I psychiatric illness based on history, physical exam, blood and urine chemistries; or self-reported history of neurological, psychiatric, or other medical condition that precludes participation, such as nervous system disorders, dementia, chronic migraines, or epilepsy; panic, bipolar or schizoaffective disorder; sleep disorders including insomnia, narcolepsy and obstructive sleep apnea; liver, kidney or heart disease, hypertension; infectious diseases; diabetes; or any other conditions for which medical monitoring is advised and which may require medications and/or lifestyles that preclude alcohol consumption and/or sleep disruption.
- Current depression as determined on the Beck Depression Inventory (Beck, 1996), by either a total score of 19 or higher or a response greater than 0 on Q9 (suicidality).
- Cardiovascular, gastrointestinal, or musculoskeletal problems, or other major conditions such as organ failure, cancer or patients requiring oxygen.
- Prior history or diagnosis of any sleep disorder including Obstructive Sleep Apnea (AHI ≥15 events/hour) - from ambulatory or in lab polysomnography; Restless legs syndrome or periodic limb movement disorder; Insomnia; Parasomnia; High Risk of OSA based on STOP-BANG Questionnaire ("yes" on at least 4 of 8 questions); High Risk of Restless Legs Syndrome (RLS) based on Cambridge-Hopkins Screening questionnaire; High Risk of Insomnia based on Insomnia Severity Index (score of 22 or higher).
- Current use or use within the past month of a prescription or over-the-counter sleep medication or stimulant (based on self-report or review with a study clinician).
- History of potential MRI contraindications, including: tinnitus; sensorineural hearing loss > 30 dB; pace maker or internal defibrillator; metallic implants (e.g. orthopedic plates after bone fractures, joint replacements, surgical staples or clips, artificial heart valves, stents, cava filters); metallic splinters (e.g. after an accident or due to war injury); non-removable dental brace; Tattoo (some tattoo inks contain metallic particles); permanent make-up; non-MRI compatible intrauterine contraceptive device; cochlear implant (implanted hearing device); medication pump; acupuncture needle; other foreign bodies/objects which are non-removable; pregnancy (or its possibility); previous brain and/or heart surgery.
- History of severe motion sickness, based on self-report or driving simulator response.
- Pregnant or currently breast feeding. People that menstruate will have a pregnancy test performed via urine sample during screening, as those that are currently pregnant are unable to participate in the study.
- Individuals who self-report severe contact dermatitis or allergy to bandages, silicone, nickel or silver.
- Currently working night, swing, split or rotating shift.
- Planned travel across more than one time zone within 7 days of the scheduled study start date.
- Habitual daytime napping.
Recruiting US locations
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA 19104
Site contact: Sierra Park-Chavar · 2155735855 · uepstudy@pennmedicine.upenn.edu
Study contacts (from the official record)
- Sierra Park-Chavar, BA · 2158989667 · sierrap@pennmedicine.upenn.edu
Similar studies in Pennsylvania
All sleep studies in Pennsylvania →- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Abington, PA + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Wyomissing, PA + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Wyomissing, PA + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Philadelphia, PA + 41 other US sites
- Eligibility basics
- Ages 18–74